{"id":"F2010L00151","name":"National Health (Pharmaceutical Benefits - Therapeutic Groups) Determination 2010 (No. PB 1 of 2010)","slug":"national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"repealed","isInForce":false,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":122922,"registerId":"commonwealth-F2010L00151-current","compilationNumber":null,"startDate":"2026-04-03","status":"Repealed","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Name of Determination","content":"#### 1 Name of Determination\n\n  (1) This Determination is the National Health (Pharmaceutical Benefits—Therapeutic Groups) Determination 2010.\n  (2) This Determination may also be cited as PB 1 of 2010.","sortOrder":0},{"sectionNumber":"4","sectionType":"section","heading":"Definitions","content":"#### 4 Definitions\n\n  In this Determination:\n\n> Act means the National Health Act 1953.\n\n> ATRA group means the Angiotensin II receptor antagonist group.\n\n> H2RA group means the H2 receptor antagonist group.","sortOrder":1},{"sectionNumber":"5","sectionType":"section","heading":"Therapeutic groups","content":"#### 5 Therapeutic groups\n\n  For paragraph 84AG(1)(a) of the Act, a therapeutic group is a group mentioned in a Part of Schedule 1.","sortOrder":2},{"sectionNumber":"6","sectionType":"section","heading":"Drugs in therapeutic groups","content":"#### 6 Drugs in therapeutic groups\n\n  For paragraph 84AG(1)(b), each listed drug mentioned in a Part of Schedule 1 is in the therapeutic group mentioned in the Part.","sortOrder":3},{"sectionNumber":"Part 2","sectionType":"part","heading":"ATRA group","content":"## Part 2—ATRA group\n\n| Item | Listed drug |\n| ---- | ----------- |\n| 2    | Eprosartan  |\n| 4    | Losartan    |","sortOrder":4},{"sectionNumber":"Part 4","sectionType":"part","heading":"H2RA group","content":"## Part 4—H2RA group\n\n| Item | Listed drug |\n| ---- | ----------- |\n| 3    | Nizatidine  |","sortOrder":5}],"analysis":{"kimi_summary":{"_metrics":{"model":"kimi-k2.5","source":"moonshot-batch","completionTokens":1349},"content_quality":"ok","complexity_score":2,"scope_assessment":{"changed":false,"description":"This foundational instrument establishes the initial therapeutic groups under the National Health Act. It operates within its original intended scope of creating specific drug groupings for PBS management."},"complexity_factors":["Only 3 defined terms in the interpretation section","Simple tabular structure listing specific drugs without conditional logic","Direct, unambiguous references to single section of parent Act (section 84AG)","No exceptions, exemptions, or nested provisions"],"plain_english_summary":"This Determination groups specific prescription medicines into \"therapeutic groups\" for the Pharmaceutical Benefits Scheme (PBS).\n\n**What it does:**\n- Creates categories of medicines that work in similar ways (called *therapeutic groups*)\n- Sets up two specific groups: **blood pressure medications** (Angiotensin II receptor antagonists, including Eprosartan and Losartan) and **stomach acid medications** (H2 receptor antagonists, including Nizatidine)\n- Allows the government to manage PBS pricing by treating similar medicines as comparable within these groups\n\n**Who it affects:**\n- Doctors prescribing these specific medicines\n- Pharmacists dispensing PBS-subsidised drugs\n- Patients receiving these medications through the PBS\n\n**Why it matters:**\nGrouping drugs this way helps control healthcare costs and streamline the subsidy system by treating therapeutically similar medicines as alternatives within the same category."}},"importantCases":[],"_links":{"self":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010","history":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010/history","analysis":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010/analysis","conflicts":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010/conflicts","importantCases":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010/important-cases","documents":"/api/acts/national-health-pharmaceutical-benefits-therapeutic-groups-determination-2010-no-pb-1-of-2010/documents"}}